Preveceutical Medical Inc · CSE:PREV
Preveceutical Medical — Investor Presentation (January 2025)
34 slides from Preveceutical Medical's investor presentation, January 2025
Slide 1: Investor Presentation
Pr eveC eu tic al Med ic a l I nc . C SE :PRE V | OTC : PRVC F | FS E: 18H Q1 - 2025 Investor Presentation biogenetherapeutics. com 1
Slide 2: Our Mission
Our Mission BioGene commits to Delivering the Future of Genetic Medicines with Precision Delivery, opening the door to alternative patient-friendly routes of LNP administration through innovative products and platforms that target key tissues of interest in obesity and diabetes… and beyond! biogenet
Slide 3: Disclaimer
DISCLAIMER This presentation and its appendices (together, the “Presentation”) have been prepared and delivered by BioGene Therapeutics Inc. (“BioGene Therapeutics” or the “Company”). The Presentation is strictly confidential and may not be reproduced or redistributed, in whole or in part, to any ot
Slide 4: Board of Directors
Board of Directors Stephen Van Deventer Deepak Sampath, PhD Steve Glover Dr. Linnéa Olofsson, PhD Patroski J. Lawson, MSP Stephen is the Deepak will serve as Steve joins BioGene as Linnéa has been as a Patroski is the founder Chairman, CEO and an Independent a Board Member, Board Member at and CEO o
Slide 5: Senior Management
Senior Management Stephen Van Deventer Alex McAuly, CPA Harry Parekh, PhD Dr. Linnéa Olofsson, PhD Louis Lapointe Stephen is the Alex serves as the Harry is welcomed to Linnéa has been Louis will be heading Chairman, CEO and Chief Financial the BioGene team as appointed Director of Business Presiden
Slide 6: Scientific and Corporate Advisory Board
Scientific and Corporate Advisory Board Prof. Mirela Delibegović Barry Ticho, MD, PhD Mariya Georgieva, PhD Brian Gallagher, Jr. Kathy Rokita As a member of Barry will serve on Mariya will serve on Brian will sit on the Kathy is joining the BioGene’s Scientific BioGene’s Scientific BioGene’s Scienti
Slide 7: BioGene Australia
BIOGENE AUSTRALIA BioGene has established a wholly-owned subsidiary in Brisbane, Queensland, Australia, to bolster their research and development interests and provide significant cash-back R&D Formulation & Preclinical Facility R&D grants from the Australian government. Brisbane Brisbane hosts a se
Slide 8: A Global Epidemic
A Global Epidemic OBESITY 1 Cases have tripled in the past decade leading to elevated risk of mortality: heart disease, stroke and dementia. DIABETES 2 1 in 10 adults are diagnosed with diabetes. Childhood rates of diabetes & obesity are on a steep upward trajectory. DRUG SIDE EFFECTS 3 Debilitating
Slide 9: Obesity Rates
Obesity Rates Obesity Cases Triple in a Decade 4,500 4,000 • The World Obesity Federation (WOF) predicts that 3,500 despite current treatments the economic impact of obesity will reach >$4 trillion annually by 2035. 3,000 in Millions 2,500 • WOF report predicts that by 2035, >HALF of the 2,000 world
Slide 10: Diabetes Rates
Diabetes Rates 1 in 8 Adults are Diabetic and Children Rates Rapidly Rise Adults Children 1,000 600,000 in Millions 400,000 500 200,000 0 0 2023 2030 2035 2040 2045 2017 2025 2040 2060 Adults Children (USA only) • Leads to >4 million adult deaths a year. • Over 570 million adults aged between 20 and
Slide 11: Weight Loss Drug Market
Weight Loss Drug Market $200Bn in the Next Decade • The weight loss drug market was circa. US$34 45 billion in 2024. 40 35 30 USD Billion • Expected to surpass US$43 billion by 2029 25 20 (CAGR >5.5%, 2024-29) 15 10 5 • Barclays capital markets projects a US$200 0 billion market by circa. 2030. 2024
Slide 12: GLP1 agonists have changed the obesity treatment paradigm but unmet medical needs remain high
GLP1 agonists have changed the obesity treatment paradigm but unmet medical needs remain high Present with an array of issues: • Severe sometimes life-threatening side effects Muscle Loss Is • 40% of patients stop treatment by one year Significant • 20-40% muscle loss • Patients build tolerance over
Slide 13: BioGene's solution
BioGene’s solution Dual Gene Therapy siRNAs targeting obesity and diabetes -> restore metabolic functions with reduced side effects, increased compliance and cost-effectiveness SOL-GEL BIORESPONSIVE DUAL GENE Smart-siRNAs PLATFORM LNP PLATFORM THERAPY Bioresponsive self- Metabolically- A versatile p
Slide 14: SOL-GEL Nose To Brain Platform Delivery
SOL-GEL Nose To Brain Platform Delivery Challenges with Oral Direct Nose-to-Brain The Blood-Brain-Barrier Olfactory Pathway Delivery Route Delivery Targeting with Sol-Gel BBB remains a universal Rapid breakdown by Desired patient outcomes hurdle for drugs intended An ideal and proven enzymes in the
Slide 15: What is the Sol-Gel Platform?
What is the Sol-Gel Platform? A solution that is engineered to rapidly gel upon contact with mucosa… • Targeted spray delivery and retention on mucosa • Controlled and sustained release (nanomicellar-formulation) to and through mucosa • Sol-Gel delivery altogether circumvents the BBB – not a hurdle
Slide 16: SOL-GEL Platform Technology & Device
SOL-GEL Platform Technology & Device Olfactory epithelia Olfactory epithelia Conventional nasal sprays deliver formulation Olfactory mucosa targeting, rapid sol-to-gel throughout the nasal cavity, and are rapidly cleared… transition, muco-retention and sustained delivery • Anterior & posterior leaka
Slide 17: Non-Viral Vector Platform - BioGene's Bioresponsive LNPs (bLNP)
Non-Viral Vector Platform - BioGene’s Bioresponsive LNPs (bLNP) Vectors possess a unique bioresponsive gene cargo- releasing feature: US Patent 11,566,044 – granted 31-Mar-23 • Efficient Delivery: The bLNP systems possess endosomal escape features AND actively releases genetic cargo from their carri
Slide 18: Key features of BioGene's Bioresponsive LNPs (bLNP)
Key features of BioGene’s Bioresponsive LNPs (bLNP) • Next generation – non-viral bioresponsive vector • US Patent # 11,566,044 granted, 31st March 2023 CRICOS code 00025B Comprehensive release of all genetic cargo from their carrier… Significant implications for precision medicine in mainstream dis
Slide 19: PTP1B Validation: Diabetes & Obesity
PTP1B Validation: Diabetes (Insulin resistance) & Obesity (leptin signaling) PTP1B directly dephopshorylates the Insulin Receptor while indirectly acting on the leptin receptor to regulate satiety through Jak2/Stat3. Dual approach : our bLNPs specifically targeting PTP1B has been uniquely designed w
Slide 20: Mice lacking neuronal PTP1B are resistant to diet induced obesity
Mice lacking neuronal PTP1B are resistant to diet induced obesity and are protected from developing leptin resistance WT WT PTP1B +/- PTP1B +/- PTP1B -/- PTP1B -/- WT PTP1B -/- WT PTP1B -/- Conclusion of the study: “for effective obesity treatment and optimal therapy for type 2 diabetes, PTP1B inhib
Slide 21: Preclinical development: downregulating PTP1B in the CNS
Preclinical development ; downregulating PTP1B in the CNS only, restores both insulin & leptin sensitivity PTP1B -/- in leptin-receptor expressing neurons Neuron-specific PTP1B -/- leads to leads to CNS • Decrease in body weight & fat mass • Leptin hypersensitivity • Increased activity and energy ex
Slide 22: PTP1B is a strong drug target candidate for obesity, T2D and other areas
PTP1B is a strong drug target candidate for obesity, T2D and other therapeutic areas PTP1B inhibition reduces neuroinflammation and fronto-temporal dementia in animal models displaying potential for the treatment of Alzheimer Source: Pharmacological PTP1B inhibition rescues motor learning, neuroinfl
Slide 23: PTPN1 Gene Targeting Strategy with BioGene's Smart-siRNAs
PTPN1 Gene Targeting Strategy with BioGene’s Smart-siRNAs PTPN1 gene comprises 10 exons, each potential targets for siRNA: 1 2 3 4 5 6 7 8 9 10 63bp 91bp 101bp 99bp 138bp 210bp 162bp 224bp 196bp 24bp 01. 02. 03. Successfully engineered siRNAs against both mouse siRNAs sequences were selective, poten
Slide 24: Potent Gene Silencing Confirmed Using BioGene's bLNPs
Potent Gene Silencing bLNP-1 Confirmed Using BioGene’s Bioresponsive LNPs (bLNPs) • bLNPs possess the unique bioresponsive ‘gene- releasing’ linker (US Patent #11,566,044 – granted 31/Mar/23) • UQP12 & UQP15 (top and bottom graphs) represent select Smart-siRNAs showing potent gene silencing bLNP-2 w
Slide 25: Planned Diabetes and Obesity Preclinical Study
Planned Diabetes and Location: The University of Queensland, Brisbane 01 ➔Extensive expertise with Sol-Gel engineering, bLNP Obesity formulation & preclinical models of obesity and diabetes Preclinical Study 02 Research Team Led by BioGene’s Chief Research Officer & Scientific Founder, Dr. Harry Par
Slide 26: Timeline
Timeline Q1 Q3-4, Q1, Q2, 2025 2025 2026 2026 Commence Announce topline Pre-clinical rodent Partnership preclinical PoC data for diabetes & obesity negotiations and diabetes and preclinical study trial concludes clinical trial obesity study with planning Smart-siRNAs & gets underway bLNPs in Sol-Gel
Slide 27: BioGene's solution
BioGene’s solution Dual Gene Therapy siRNAs targeting obesity and diabetes -> restore metabolic functions with reduced side effects, increased compliance and cost-effectiveness SOL-GEL BIORESPONSIVE DUAL GENE Smart-siRNAs PLATFORM LNP PLATFORM THERAPY Bioresponsive self- Metabolically- A versatile p
Slide 28: Accessing non-dilutive funding from the Australian MRFF grant scheme
Accessing non-dilutive funding from the Australian Medical Research Future Fund (MRFF) grant scheme • The Medical Research Future Fund (MRFF) ‘Research Translation’ is one of 4 main is a $20 billion long-term investment priority themes: supporting Australian health and • Examples grant call typicall
Slide 29: The Landscape is Rapidly Evolving to Next Generation Therapies
The Landscape is Rapidly Evolving to Next Generation Therapies biogenetherapeutics. com 29
Slide 30: Revenue and Corporate Strategy
Revenue and Corporate Strategy Platform Acquisition and Direct Listing Licensing Partnerships on NASDAQ Potential biogenetherapeutics. com 30
Slide 31: Global Collaborators
Global Collaborators biogenetherapeutics. com 31
Slide 32: Thank You
Thank You Pr eveC eu tic al Med ic a l I nc . C SE:PRE V | OTC :PRV CF | F SE:18 H Contact Page ir@biogenetherapeutics.com biogenetherapeutics.com biogenetherapeutics. com 32
Slide 33: Source
Source biogenetherapeutics. com 33
Slide 34: Sources
Sources 1. ht tp s://www.ma yo clin ic. org /d rug s-su pp lemen ts /semaglut id e -su bc uta neous - rout e/s ide - effect s/d rg -20406730?p=1 1. cn bc. com - Obes it y drug indu st ry cou ld be wo rt h $200 b illio n with in th e deca de, sa ys Barc la ys 1. news.harvard.edu - Are new weight-loss
PreveCeutical Medical — Investor Presentation (January 2025) on 6ix